Abstract
BackgroundImmune checkpoint inhibitors (ICIs) have become a mainstay of cancer treatment. Their immune-boosting quality has one major drawback, their proclivity to induce a broad array of immune-related adverse events (irAEs)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have